Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination

Population Health Metrics

Volumn 5, Issue , 2007, Pages

  Goldhaber Fiebert, Jeremy D ^a   Stout, Natasha K ^a   Ortendahl, Jesse ^a   Kuntz, Karen M ^a,b   Goldie, Sue J ^a   Salomon, Joshua A ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; AGE; ANALYTICAL PARAMETERS; ARTICLE; CALIBRATION; CANCER INCIDENCE; CANCER MODEL; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COMPUTER SIMULATION; CONDYLOMA; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA SYNTHESIS; DECISION SUPPORT SYSTEM; DISEASE COURSE; EPIDEMIOLOGICAL DATA; HEALTH CARE POLICY; HIGH RISK PATIENT; INFECTION PREVENTION; INTERMETHOD COMPARISON; MASS SCREENING; PHARMACEUTICAL CARE; PREDICTION; PREVALENCE; PREVENTIVE HEALTH SERVICE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; STOCHASTIC MODEL; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; WART VIRUS;

EID: 38649089761     PISSN: None     EISSN: 14787954     Source Type: Journal    
DOI: 10.1186/1478-7954-5-11     Document Type: Article

References (140)

1. Kitchener HC Castle PE Cox JT Chapter 7: Achievements and limitations of cervical cytology screening Vaccine 2006, 24(Suppl 3):S63-S70 10.1016/ j.vaccine.2006.05.113 16950019
2. Saraiya M Ahmed F Krishnan S Richards TB Unger ER Lawson HW Cervical cancer incidence in a prevaccine era in the United States, 1998-2002 Obstet Gynecol 2007, 109:360-370 17267837
3. Singh GK Miller BA Hankey BF Edwards BK Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975-2000 Cancer 2004, 101:1051-1057 10.1002/cncr.20467 15329915
4. Yabroff KR Lawrence WF King JC Mangan P Washington KS Yi B Kerner JF Mandelblatt JS Geographic disparities in cervical cancer mortality: What are the roles of risk factor prevalence, screening, and use of recommended treatment? J Rural Health 2005, 21:149-157 10.1111/ j.1748-0361.2005.tb00075.x 15859052
5. Koutsky LA Harper DM Chapter 13: Current findings from prophylactic HPV vaccine trials Vaccine 2006, 24(Suppl 3):S114-S121 10.1016/ j.vaccine.2006.06.014 16949998
6. Goldie SJ Goldhaber-Fiebert JD Garnett GP Chapter 18: Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling Vaccine 2006, 24(Suppl 3):S155-S163 10.1016/j.vaccine.2006.05.112 16950003
7. Koliopoulos G Arbyn M Martin-Hirsch P Kyrgiou M Prendiville W Paraskevaidis E Diagnostic accuracy of human papillomavirus testing in primary cervical screening: A systematic review and meta-analysis of non-randomized studies Gynecol Oncol 2007, 104:232-246 10.1016/ j.ygyno.2006.08.053 17084886
8. Cuzick J Clavel C Petry KU Meijer CJ Hoyer H Ratnam S Szarewski A Birembaut P Kulasingam S Sasieni P Iftner T Overview of the European and North American studies on HPV testing in primary cervical cancer screening Int J Cancer 2006, 119:1095-1101 10.1002/ijc.21955 16586444
9. Prorok PC Andriole GL Bresalier RS Buys SS Chia D Crawford ED Fogel R Gelmann EP Gilbert F Hasson MA Hayes RB Johnson CC Mandel JS Oberman A O'Brien B Oken MM Rafla S Reding D Rutt W Weissfeld JL Yokochi L Gohagan JK Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Control Clin Trials 2000, 21:273S-309S 10.1016/ S0197-2456(00)00098-2 11189684
10. Bidus MA Maxwell GL Kulasingam S Rose GS Elkas JC Chernofsky M Myers ER Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening Obstet Gynecol 2006, 107:997-1005 16648402
11. Goldie SJ Weinstein MC Kuntz KM Freedberg KA The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women Ann Intern Med 1999, 130:97-107 10068381
12. Goldie SJ Kim JJ Wright TC Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more Obstet Gynecol 2004, 103:619-631 15051550
13. Goldie SJ Gaffikin L Goldhaber-Fiebert JD Gordillo-Tobar A Levin C Mahe C Wright TC Cost-effectiveness of cervical-cancer screening in five developing countries N Engl J Med 2005, 353:2158-2168 10.1056/ NEJMsa044278 16291985
14. Kim JJ Wright TC Goldie SJ Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance JAMA 2002, 287:2382-2390 10.1001/jama.287.18.2382 11988059
15. Kim JJ Leung GM Woo PP Goldie SJ Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong J Public Health (Oxf) 2004, 26:130-137 10.1093/pubmed/fdh138 15284314
16. Kim JJ Wright TC Goldie SJ Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy J Natl Cancer Inst 2005, 97:888-895 15956650
17. Kulasingam SL Myers ER Lawson HW McConnell KJ Kerlikowske K Melnikow J Washington AE Sawaya GF Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests Obstet Gynecol 2006, 107:321-328 16449119
18. Mandelblatt JS Lawrence WF Womack SM Jacobson D Yi B Hwang YT Gold K Barter J Shah K Benefits and costs of using HPV testing to screen for cervical cancer JAMA 2002, 287:2372-2381 10.1001/jama.287.18.2372 11988058
19. Mandelblatt JS Lawrence WF Gaffikin L Limpahayom KK Lumbiganon P Warakamin S King J Yi B Ringers P Blumenthal PD Costs and benefits of different strategies to screen for cervical cancer in less-developed countries J Natl Cancer Inst 2002, 94:1469-1483 12359856
20. McCrory DC Matchar DB Bastian L Datta S Hasselblad V Hickey J Myers E Nanda K Evaluation of cervical cytology Evid Rep Technol Assess (Summ) 1999, 1-6 11925972
21. Myers ER McCrory DC Nanda K Bastian L Matchar DB Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis Am J Epidemiol 2000, 151:1158-1171 10905528
22. Kim JJ Kuntz KM Stout NK Mahmud SM Villa LL Franco EL Goldie SJ Multi-parameter calibration of a natural history model of cervical cancer Am J Epidemiol 2007
23. Hildesheim A Schiffman MH Gravitt PE Glass AG Greer CE Zhang T Scott DR Rush BB Lawler P Sherman ME Persistence of type-specific human papillomavirus infection among cytologically normal women J Infect Dis 1994, 169:235-240 8106758
24. Ho GY Bierman R Beardsley L Chang CJ Burk RD Natural history of cervicovaginal papillomavirus infection in young women N Engl J Med 1998, 338:423-428 10.1056/NEJM199802123380703 9459645
25. Liu T Soong SJ Alvarez RD Butterworth CE Jr A longitudinal analysis of human papillomavirus 16 infection, nutritional status, and cervical dysplasia progression Cancer Epidemiol Biomarkers Prev 1995, 4:373-380 7655333
26. Munoz N Mendez F Posso H Molano M van den Brule AJ Ronderos M Meijer C Munoz A Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results J Infect Dis 2004, 190:2077-2087 10.1086/425907 15551205
27. Sun XW Kuhn L Ellerbrock TV Chiasson MA Bush TJ Wright TC Jr Human papillomavirus infection in women infected with the human immunodeficiency virus N Engl J Med 1997, 337:1343-1349 10.1056/ NEJM199711063371903 9358128
28. Ellerbrock TV Chiasson MA Bush TJ Sun XW Sawo D Brudney K Wright TC Jr Incidence of cervical squamous intraepithelial lesions in HIV-infected women JAMA 2000, 283:1031-1037 10.1001/jama.283.8.1031 10697063
29. Ho GY Burk RD Klein S Kadish AS Chang CJ Palan P Basu J Tachezy R Lewis R Romney S Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia J Natl Cancer Inst 1995, 87:1365-1371 10.1093/jnci/87.18.1365 7658497
30. Ho GY Kadish AS Burk RD Basu J Palan PR Mikhail M Romney SL HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia Int J Cancer 1998, 78:281-285 10.1002/ (SICI)1097-0215(19981029)78:3<281::AID-IJC3>3.0.CO;2-R 9766558
31. Hopman EH Rozendaal L Voorhorst FJ Walboomers JM Kenemans P Helmerhorst TJ High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy BJOG 2000, 107:600-604 10.1111/j.1471-0528.2000.tb13299.x 10826572
32. Koutsky LA Holmes KK Critchlow CW Stevens CE Paavonen J Beckmann AM DeRouen TA Galloway DA Vernon D Kiviat NB A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection N Engl J Med 1992, 327:1272-1278 1328880
33. Londesborough P Ho L Terry G Cuzick J Wheeler C Singer A Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities Int J Cancer 1996, 69:364-368 10.1002/ (SICI)1097-0215(19961021)69:5<364::AID-IJC2>3.0.CO;2-3 8900368
34. Nobbenhuis MA Walboomers JM Helmerhorst TJ Rozendaal L Remmink AJ Risse EK van der Linden HC Voorhorst FJ Kenemans P Meijer CJ Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study Lancet 1999, 354:20-25 10.1016/S0140-6736(98)12490-X 10406360
35. Remmink AJ Walboomers JM Helmerhorst TJ Voorhorst FJ Rozendaal L Risse EK Meijer CJ Kenemans P The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months Int J Cancer 1995, 61:306-311 10.1002/ijc.2910610305 7729939
36. Rozendaal L Walboomers JM van der Linden JC Voorhorst FJ Kenemans P Helmerhorst TJ van BM Meijer CJ PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears Int J Cancer 1996, 68:766-769 10.1002/(SICI)1097-0215(19961211)68:6<766::AID-IJC13>3.0.CO;2-Z 8980181
37. Syrjanen K Kataja V Yliskoski M Chang F Syrjanen S Saarikoski S Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System Obstet Gynecol 1992, 79:675-682 1314359
38. Melnikow J Nuovo J Willan AR Chan BK Howell LP Natural history of cervical squamous intraepithelial lesions: A meta-analysis Obstet Gynecol 1998, 92:727-735 10.1016/S0029-7844(98)00245-2 9764690
39. Ostor AG Natural history of cervical intraepithelial neoplasia: A critical review Int J Gynecol Pathol 1993, 12:186-192 10.1097/ 00004347-199304000-00018 8463044
40. Franco EL Villa LL Sobrinho JP Prado JM Rousseau MC Desy M Rohan TE Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer J Infect Dis 1999, 180:1415-1423 10.1086/315086 10515798
41. Schlecht NF Platt RW Duarte-Franco E Costa MC Sobrinho JP Prado JC Ferenczy A Rohan TE Villa LL Franco EL Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia J Natl Cancer Inst 2003, 95:1336-1343 12953088
42. Surveillance, Epidemiology, End Results (SEER) Cancer Statistics Review, 1975-2001 http://seer.cancer.gov/csr/1975_2001/
43. Cancer Incidence in Five Continents New York: International Union against Cancer, Springer-Verlag 1966
44. US Lifetables for Females http://www.cdc.gov/nchs/products/pubs/pubd/ lftbls/lftbls.htm
45. CDC/DPH Multi-Center HPV and Cytology Primary Data 2005
46. Bauer HM Hildesheim A Schiffman MH Glass AG Rush BB Scott DR Cadell DM Kurman RJ Manos MM Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon Sex Transm Dis 1993, 20:274-278 8235925
47. Brown DR Shew ML Qadadri B Neptune N Vargas M Tu W Juliar BE Breen TE Fortenberry JD A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women J Infect Dis 2005, 191:182-192 10.1086/426867 15609227
48. Burk RD Kelly P Feldman J Bromberg J Vermund SH DeHovitz JA Landesman SH Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors Sex Transm Dis 1996, 23:333-341 8836027
49. Chaturvedi AK Dumestre J Gaffga AM Mire KM Clark RA Braly PS Dunlap K Beckel TE Hammons AF Kissinger PJ Hagensee ME Prevalence of human papillomavirus genotypes in women from three clinical settings J Med Virol 2005, 75:105-113 10.1002/jmv.20244 15543579
50. Giuliano AR Papenfuss M Abrahamsen M Denman C de Zapien JG Henze JL Ortega L Brown de Galaz EM Stephan J Feng J Baldwin S Garcia F Hatch K Human papillomavirus infection at the United States-Mexico border: implications for cervical cancer prevention and control Cancer Epidemiol Biomarkers Prev 2001, 10:1129-1136 11700260
51. Hildesheim A Gravitt P Schiffman MH Kurman RJ Barnes W Jones S Tchabo JG Brinton LA Copeland C Epp J Determinants of genital human papillomavirus infection in low-income women in Washington, D.C Sex Transm Dis 1993, 20:279-285 8235926
52. Jacobson DL Womack SD Peralta L Zenilman JM Feroli K Maehr J Daniel RW Shah KV Concordance of human papillomavirus in the cervix and urine among inner city adolescents Pediatr Infect Dis J 2000, 19:722-728 10959740
53. Kotloff KL Wasserman SS Russ K Shapiro S Daniel R Brown W Frost A Tabara SO Shah K Detection of genital human papillomavirus and associated cytological abnormalities among college women Sex Transm Dis 1998, 25:243-250 10.1097/00007435-199805000-00005 9587175
54. Ley C Bauer HM Reingold A Schiffman MH Chambers JC Tashiro CJ Manos MM Determinants of genital human papillomavirus infection in young women J Natl Cancer Inst 1991, 83:997-1003 10.1093/jnci/83.14.997 1649312
55. Moscicki AB Genital HPV infections in children and adolescents Obstet Gynecol Clin North Am 1996, 23:675-697 8869952
56. Moscicki AB Ellenberg JH Vermund SH Holland CA Darragh T Crowley-Nowick PA Levin L Wilson CM Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: Impact of infection with human immunodeficiency virus Arch Pediatr Adolesc Med 2000, 154:127-134 10665598
57. Peyton CL Gravitt PE Hunt WC Hundley RS Zhao M Apple RJ Wheeler CM Determinants of genital human papillomavirus detection in a US population J Infect Dis 2001, 183:1554-1564 10.1086/320696 11343204
58. Sellors JW Mahony JB Kaczorowski J Lytwyn A Bangura H Chong S Lorincz A Dalby DM Janjusevic V Keller JL Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group CMAJ 2000, 163:503-508 80454 11006760
59. Sellors JW Karwalajtys TL Kaczorowski JA Mahony JB Lytwyn A Chong S Sparrow J Lorincz A Prevalence of infection with carcinogenic human papillomavirus among older women CMAJ 2002, 167:871-873 128399 12406945
60. Smith EM Ritchie JM Levy BT Zhang W Wang D Haugen TH Turek LP Prevalence and persistence of human papillomavirus in postmenopausal age women Cancer Detect Prev 2003, 27:472-480 10.1016/S0361-090X(03)00104-1 14642556
61. Tarkowski TA Koumans EH Sawyer M Pierce A Black CM Papp JR Markowitz L Unger ER Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population J Infect Dis 2004, 189:46-50 10.1086/380466 14702152
62. Benard VB Eheman CR Lawson HW Blackman DK Anderson C Helsel W Thames SF Lee NC Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995-2001 Obstet Gynecol 2004, 103:564-571 14990422
63. Bibbo M Keebler CM Wied GL Prevalence and incidence rates of cervical atypia. A computerized file analysis of 148,735 patients J Reprod Med 1971, 6:184-188 5098095
64. Halcon LL Lifson AR Shew M Joseph M Hannan PJ Hayman CR Pap test results among low-income youth: Prevalence of dysplasia and practice implications J Obstet Gynecol Neonatal Nurs 2002, 31:294-304 10.1111/ j.1552-6909.2002.tb00051.x 12033542
65. Insinga RP Glass AG Rush BB Diagnoses and outcomes in cervical cancer screening: A population-based study Am J Obstet Gynecol 2004, 191:105-113 10.1016/j.ajog.2004.01.043 15295350
66. Lawson HW Lee NC Thames SF Henson R Miller DS Cervical cancer screening among low-income women: Results of a national screening program, 1991-1995 Obstet Gynecol 1998, 92:745-752 10.1016/S0029-7844(98)00257-9 9794662
67. Mangan SA Legano LA Rosen CM McHugh MT Fierman AH Dreyer BP Palusci VJ Winkler B Increased prevalence of abnormal Papanicolaou smears in urban adolescents Arch Pediatr Adolesc Med 1997, 151:481-484 9158440
68. Sadeghi SB Hsieh EW Gunn SW Prevalence of cervical intraepithelial neoplasia in sexually active teenagers and young adults. Results of data analysis of mass Papanicolaou screening of 796,337 women in the United States in 1981 Am J Obstet Gynecol 1984, 148:726-729 6702940
69. Sadeghi SB Sadeghi A Robboy SJ Prevalence of dysplasia and cancer of the cervix in a nationwide, planned parenthood population Cancer 1988, 61:2359-2361 10.1002/ 1097-0142(19880601)61:11<2359::AID-CNCR2820611135>3.0.CO;2-7 3365664
70. Snyder RN Ortiz Y Willie S Cove JK Dysplasia and carcinoma in situ of the uterine cervix: Prevalence in very young women (under age 22). A one-year study in a health plan population Am J Obstet Gynecol 1976, 124:751-756 1258935
71. Stany MP Bidus MA Reed EJ Kaplan KJ McHale MT Rose GS Elkas JC The prevalence of HR-HPV DNA in ASC-US Pap smears: A military population study Gynecol Oncol 2006, 101:82-85 10.1016/j.ygyno.2005.09.050 16290002
72. Adam E Kaufman RH Berkova Z Icenogle J Reeves WC Is human papillomavirus testing an effective triage method for detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia? Am J Obstet Gynecol 1998, 178:1235-1244 10.1016/S0002-9378(98)70328-X 9662307
73. Aoyama C Peters J Senadheera S Liu P Shimada H Uterine cervical dysplasia and cancer: Identification of c-myc status by quantitative polymerase chain reaction Diagn Mol Pathol 1998, 7:324-330 10.1097/ 00019606-199812000-00006 10207671
74. Bosch FX Manos MM Munoz N Sherman M Jansen AM Peto J Schiffman MH Moreno V Kurman R Shah KV Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group J Natl Cancer Inst 1995, 87:796-802 10.1093/jnci/87.11.796 7791229
75. Brown DR Legge D Qadadri B Distribution of human papillomavirus types in cervicovaginal washings from women evaluated in a sexually transmitted diseases clinic Sex Transm Dis 2002, 29:763-768 10.1097/ 00007435-200212000-00005 12466717
76. Burger RA Monk BJ Kurosaki T nton-Culver H Vasilev SA Berman ML Wilczynski SP Human papillomavirus type 18: Association with poor prognosis in early stage cervical cancer J Natl Cancer Inst 1996, 88:1361-1368 10.1093/jnci/88.19.1361 8827013
77. Burnett AF Barnes WA Johnson JC Grendys E Willett GD Barter JF Doniger J Prognostic significance of polymerase chain reaction detected human papillomavirus of tumors and lymph nodes in surgically treated stage IB cervical cancer Gynecol Oncol 1992, 47:343-347 10.1016/ 0090-8258(92)90137-8 1335431
78. Cox JT Schiffman M Solomon D Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy Am J Obstet Gynecol 2003, 188:1406-1412 10.1067/mob.2003.461 12824970
79. Evans MF Mount SL Beatty BG Cooper K Biotinyl-tyramide-based in situ hybridization signal patterns distinguish human papillomavirus type and grade of cervical intraepithelial neoplasia Mod Pathol 2002, 15:1339-1347 10.1038/modpathol.3880698 12481016
80. Jarboe EA Thompson LC Heinz D McGregor JA Shroyer KR Telomerase and human papillomavirus as diagnostic adjuncts for cervical dysplasia and carcinoma Hum Pathol 2004, 35:396-402 10.1016/j.humpath.2003.08.028 15116318
81. Liaw KL Glass AG Manos MM Greer CE Scott DR Sherman M Burk RD Kurman RJ Wacholder S Rush BB Cadell DM Lawler P Tabor D Schiffman M Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions J Natl Cancer Inst 1999, 91:954-960 10.1093/jnci/91.11.954 10359548
82. Paquette RL Lee YY Wilczynski SP Karmakar A Kizaki M Miller CW Koeffler HP Mutations of p53 and human papillomavirus infection in cervical carcinoma Cancer 1993, 72:1272-1280 10.1002/ 1097-0142(19930815)72:4<1272::AID-CNCR2820720420>3.0.CO;2-Q 8393371
83. Resnick RM Cornelissen MT Wright DK Eichinger GH Fox HS ter SJ Manos MM Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers J Natl Cancer Inst 1990, 82:1477-1484 10.1093/jnci/82.18.1477 2167986
84. Richardson H Kelsall G Tellier P Voyer H Abrahamowicz M Ferenczy A Coutlee F Franco EL The natural history of type-specific human papillomavirus infections in female university students Cancer Epidemiol Biomarkers Prev 2003, 12:485-490 12814991
85. Schiff M Miller J Masuk M van Asselt KL Altobelli KK Wheeler CM Becker TM Contraceptive and reproductive risk factors for cervical intraepithelial neoplasia in American Indian women Int J Epidemiol 2000, 29:983-990 10.1093/ije/29.6.983 11101538
86. Schwartz SM Daling JR Shera KA Madeleine MM McKnight B Galloway DA Porter PL McDougall JK Human papillomavirus and prognosis of invasive cervical cancer: A population-based study J Clin Oncol 2001, 19:1906-1915 11283122
87. Sebbelov AM Davidson M Kruger KS Jensen H Gregoire L Hawkins I Parkinson AJ Norrild B Comparison of human papillomavirus genotypes in archival cervical cancer specimens from Alaska natives, Greenland natives and Danish Caucasians Microbes Infect 2000, 2:121-126 10.1016/ S1286-4579(00)00276-8 10742684
88. Sellors JW Lorincz AT Mahony JB Mielzynska I Lytwyn A Roth P Howard M Chong S Daya D Chapman W Chernesky M Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions CMAJ 2000, 163:513-518 80457 11006761
89. Tran-Thanh D Provencher D Koushik A Duarte-Franco E Kessous A Drouin P Wheeler CM Dubuc-Lissoir J Gauthier P Allaire G Vauclair R Dipaolo JA Gravitt P Franco E Coutlee F Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix Am J Obstet Gynecol 2003, 188:129-134 10.1067/mob.2003.66 12548206
90. Wistuba II Montellano FD Milchgrub S Virmani AK Behrens C Chen H Ahmadian M Nowak JA Muller C Minna JD Gazdar AF Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma Cancer Res 1997, 57:3154-3158 9242443
91. Clifford GM Smith JS Aguado T Franceschi S Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis Br J Cancer 2003, 89:101-105 10.1038/sj.bjc.6601024 12838308
92. Clifford GM Smith JS Plummer M Munoz N Franceschi S Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis Br J Cancer 2003, 88:63-73 10.1038/sj.bjc.6600688 12556961
93. Clifford GM Rana RK Franceschi S Smith JS Gough G Pimenta JM Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer Cancer Epidemiol Biomarkers Prev 2005, 14:1157-1164 10.1158/ 1055-9965.EPI-04-0812 15894666
94. Kulasingam SL Hughes JP Kiviat NB Mao C Weiss NS Kuypers JM Koutsky LA Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: Comparison of sensitivity, specificity, and frequency of referral JAMA 2002, 288:1749-1757 10.1001/jama.288.14.1749 12365959
95. Khan MJ Castle PE Lorincz AT Wacholder S Sherman M Scott DR Rush BB Glass AG Schiffman M The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice J Natl Cancer Inst 2005, 97:1072-1079 16030305
96. Schiffman M Adrianza ME ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants Acta Cytol 2000, 44:726-742 11015972
97. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 9 Regs Public-Use (Nov 2004 Sub (1973-2003) based on the November 2005 submission) National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch 2006
98. Hewitt M Devesa SS Breen N Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey Prev Med 2004, 39:270-278 10.1016/j.ypmed.2004.03.035 15226035
99. Parazzini F Hildesheim A Ferraroni M La VC Brinton LA Relative and attributable risk for cervical cancer: A comparative study in the United States and Italy Int J Epidemiol 1990, 19:539-545 10.1093/ije/19.3.539 2135870
100. Schairer C Brinton LA Devesa SS Ziegler RG Fraumeni JF Jr Racial differences in the risk of invasive squamous-cell cervical cancer Cancer Causes Control 1991, 2:283-290 10.1007/BF00051667 1834239
101. Shields TS Brinton LA Burk RD Wang SS Weinstein SJ Ziegler RG Studentsov YY McAdams M Schiffman M A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human papillomavirus Cancer Epidemiol Biomarkers Prev 2004, 13:1574-1582 15466972
102. Sirovich BE Welch HG The frequency of Pap smear screening in the United States J Gen Intern Med 2004, 19:243-250 1492158 15009779 10.1111/ j.1525-1497.2004.21107.x
103. Kim JJ Folse H Murray M Goldie SJ Should Men Be Included in a Vaccination Program Against HPV Infection in a Resource-Constrained Setting? International Papillomavirus Conference and Clinical Workshop, Prague, Czech Republic
104. Agresti A Coull B Approximate is better than "exact" for interval estimation of binomial proportions The American Statistician 1998, 52:119-126 10.2307/2685469
105. Systematic reviews in health care: Meta-analysis in context London: BMJ 2001
106. Fay MP Pfeiffer R Cronin KA Le C Feuer EJ Age-conditional probabilities of developing cancer Stat Med 2003, 22:1837-1848 1475950 12754719 10.1002/sim.1428
107. Fay MP Estimating age conditional probability of developing disease from surveillance data Popul Health Metr 2004, 2:6 517510 15279675 10.1186/ 1478-7954-2-6
108. Ades AE Sculpher M Sutton A Abrams K Cooper N Welton N Lu G Bayesian methods for evidence synthesis in cost-effectiveness analysis Pharmacoeconomics 2006, 24:1-19 10.2165/00019053-200624010-00001 16445299
109. Ades AE Claxton K Sculpher M Evidence synthesis, parameter correlation and probabilistic sensitivity analysis Health Econ 2006, 15:373-381 10.1002/hec.1068 16389628
110. McMahon PM Zaslavsky AM Weinstein MC Kuntz KM Weeks JC Gazelle GS Estimation of mortality rates for disease simulation models using Bayesian evidence synthesis Med Decis Making 2006, 26:497-511 10.1177/ 0272989X06291326 16997927
111. Salomon JA Weinstein MC Hammitt JK Goldie SJ Empirically calibrated model of hepatitis C virus infection in the United States Am J Epidemiol 2002, 156:761-773 10.1093/aje/kwf100 12370165
112. Fryback DG Stout NK Rosenberg MA Trentham-Dietz A Kuruchittham V Remington PL The Wisconsin Breast Cancer Epidemiology Simulation Model J Natl Cancer Inst Monogr 2006, 37-47 17032893
113. Berry DA Inoue L Shen Y Venier J Cohen D Bondy M Theriault R Munsell MF Modeling the impact of treatment and screening on U.S. breast cancer mortality: A Bayesian approach J Natl Cancer Inst Monogr 2006, 30-36 17032892
114. Law AM Kelton WD Simulation Modeling and Analysis Boston: McGraw-Hill 2000
115. Rodriguez-Fernandez M Egea JA Banga JR Novel metaheuristic for parameter estimation in nonlinear dynamic biological systems BMC Bioinformatics 2006, 7:483 1654195 17081289 10.1186/1471-2105-7-483
116. Stevenson MD Oakley J Chilcott JB Gaussian process modeling in conjunction with individual patient simulation modeling: A case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis Med Decis Making 2004, 24:89-100 10.1177/0272989X03261561 15005958
117. O'hagan A Stevenson M Madan J Monte Carlo probabilistic sensitivity analysis for patient level simulation models: Efficient estimation of mean and variance using ANOVA Health Econ 2007, 16(10):1009-1023 10.1002/ hec.1199 17173339
118. Shechter SM Schaefer AJ Braithwaite RS Roberts MS Increasing the efficiency of Monte Carlo cohort simulations with variance reduction techniques Med Decis Making 2006, 26:550-553 10.1177/0272989X06290489 16997930
119. Habbema JD van Oortmarssen GJ Lubbe JT van der Maas PJ Model building on the basis of Dutch cervical cancer screening data Maturitas 1985, 7:11-20 10.1016/0378-5122(85)90030-1 4021825
120. van den Akker-van Marle M van BM van Oortmarssen GJ Boer R Habbema JD Cost-effectiveness of cervical cancer screening: Comparison of screening policies J Natl Cancer Inst 2002, 94:193-204 11830609
121. Goldie SJ Grima D Kohli M Wright TC Weinstein M Franco E A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine Int J Cancer 2003, 106:896-904 10.1002/ijc.11334 12918067
122. Goldie SJ Kohli M Grima D Weinstein MC Wright TC Bosch FX Franco E Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine J Natl Cancer Inst 2004, 96:604-615 15100338
123. Kulasingam SL Myers ER Potential health and economic impact of adding a human papillomavirus vaccine to screening programs JAMA 2003, 290:781-789 10.1001/jama.290.6.781 12915431
124. Sanders GD Taira AV Cost-effectiveness of a potential vaccine for human papillomavirus Emerg Infect Dis 2003, 9:37-48 12533280
125. Van de Velde N Brisson M Boily MC Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty Am J Epidemiol 2007, 17276976
126. Barnabas RV Laukkanen P Koskela P Kontula O Lehtinen M Garnett GP Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling analyses PLoS Med 2006, 3:e138 1434486 16573364 10.1371/journal.pmed.0030138
127. French KM Barnabas RV Lehtinen M Kontula O Pukkala E Dillner J Garnett GP Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland Br J Cancer 2007, 96:514-518 10.1038/sj.bjc.6603575 17245341
128. Elbasha EH Dasbach EJ Insinga RP Model for Assessing Human Papillomavirus Vaccination Strategies Emerg Infect Dis 2007, 13:28-41 17370513
129. Taira AV Neukermans CP Sanders GD Evaluating human papillomavirus vaccination programs Emerg Infect Dis 2004, 10:1915-1923 15550200
130. Hughes JP Garnett GP Koutsky L The theoretical population-level impact of a prophylactic human papilloma virus vaccine Epidemiology 2002, 13:631-639 10.1097/00001648-200211000-00006 12410003
131. Burchell AN Richardson H Mahmud SM Trottier H Tellier PP Hanley J Coutlee F Franco EL Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada Am J Epidemiol 2006, 163:534-543 10.1093/aje/kwj077 16421235
132. Parkin DM Bray F Chapter 2: The burden of HPV-related cancers Vaccine 2006, 24(Suppl 3):S11-S25 10.1016/j.vaccine.2006.05.111 16949997
133. Dunne EF Unger ER Sternberg M McQuillan G Swan DC Patel SS Markowitz LE Prevalence of HPV Infection Among Females in the United States JAMA
134. Campbell H Briggs A Buxton M Kim L Thompson S The credibility of health economic models for health policy decision-making: The case of population screening for abdominal aortic aneurysm J Health Serv Res Policy 2007, 12:11-17 10.1258/135581907779497594 17244392
135. Baggaley RF Ferguson NM Garnett GP The epidemiological impact of antiretroviral use predicted by athematical models: A review Emerg Themes Epidemiol 2005, 2:9 1242350 16153307 10.1186/1742-7622-2-9
136. Brown ML Fintor L Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature Breast Cancer Res Treat 1993, 25:113-118 10.1007/BF00662136 8347843
137. Berry DA Cronin KA Plevritis SK Fryback DG Clarke L Zelen M Mandelblatt JS Yakovlev AY Habbema JD Feuer EJ Effect of screening and adjuvant therapy on mortality from breast cancer N Engl J Med 2005, 353:1784-1792 10.1056/NEJMoa050518 16251534
138. Cronin KA Feuer EJ Clarke LD Plevritis SK Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: Comparison of mortality results from the cisnet breast cancer base case analysis J Natl Cancer Inst Monogr 2006, 112-121 17032901
139. Hojberg AL Refsgaard JC Model uncertainty - parameter uncertainty versus conceptual models Water Sci Technol 2005, 52:177-186 16304950
140. Brisson M Edmunds WJ Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs Med Decis Making 2006, 26:434-446 10.1177/0272989X06290485 16997923